Internal Medicine - Issue 2/2022
Editorial
79
Main Topic
82
Prediabetes
Hana Rosolová
85
89
Review Articles
104
What do the new ESC Guidelines for the treatment of heart failure bring to internists?
Jindřich Špinar, Lenka Špinarová, Jiří Vítovec
111
116
Colorectal cancer in patients with diabetes – epidemiology, pathophysiology and applications for clinical practice
Alexandra Romanová, Jana Malinovská, Michala Lustigová, Jana Urbanová, Ludmila Brunerová, Veronika Vejtasová, Ankita Verma, Tung A. Duong, Jan Šťovíček, Jan Brož
In Brief
124
Any expectations from the more powerful dulaglutide?
Jan Škrha jr.
127
Pituitary incidentaloma
Michal Kršek
131
Internal Medicine
2022 Issue 2
Most read in this issue
- Oral semaglutide – Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice
- The position of SGLT2 inhibitors in current medical practice – update 2022
- Prediabetes
- Anticoagulation in cancer patients; new recommendations based on randomized clinical trials